This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epocrates Invests In Future Physicians

SAN MATEO, Calif., Aug. 17, 2012 (GLOBE NEWSWIRE) -- Fueling the medical minds of tomorrow is crucial to providing the best-trained and most resourceful healthcare workforce in the future. Epocrates, Inc. (Nasdaq:EPOC), developer of the top medical app among U.S. physicians, is investing in education and care quality by offering free subscriptions for its premium mobile product to all U.S. medical students. The next generation of physicians is now heading back to school with an essential tool – Epocrates® Essentials drug, disease and diagnosis reference — at no cost.

"With more Americans potentially entering the healthcare system, future physicians will need access to top-notch training and the latest innovations. At Epocrates, we feel it is our responsibility to provide our nation's medical students with a key resource that will help advance their education, and ultimately, their ability to deliver efficient, quality care," said Andy Hurd, Epocrates' president and chief executive officer.

Many top medical schools, such as Yale School of Medicine and Drexel University College of Medicine, recommend or require students to have a mobile device loaded with the Epocrates app. The majority of medical students use mobile devices, primarily Apple iPhone smartphones, to access critical drug and safety information in real time. Whether studying pharmacology in the classroom or seeing patients on hospital rounds, many students already access the Epocrates application on their mobile devices. Now, with complimentary Epocrates Essentials subscriptions ($159), medical students will have additional decision support tools on-hand including lab interpretation guides, evidence-based treatment guidelines, differential diagnoses and disease images.

"As a fourth year medical student, Epocrates is indispensable to me and my education," said medical student Meredith Baker. "It is the first place I go with a question, and will be my right hand in practice too."

More than 40 percent of medical students also indicate that mobile medical applications are the first place they turn to for answers to a clinical question, according to Epocrates' sixth annual Future Physicians of America Survey. For additional insights about today's medical students, join the Epocrates webinar featuring the 2012 survey results.

Future Physicians of America Webinar

What: The seventh annual Future Physicians of America Survey addresses a variety of timely topics and insights including:
  • Opinions about healthcare reform and legislation
  • Future career goals and expectations
  • Mobile technology usage
  • Clinical training strengths and weaknesses

When: Thursday, September 13, 2012 at 2:00 p.m. ET

Where: Reserve a webinar spot now at .

About Epocrates, Inc.

Epocrates, Inc. (Nasdaq:EPOC) is recognized for developing the top medical application among U.S. physicians for clinical content, practice tools and health industry engagement at the point of care. Epocrates has established a loyal network of more than one million healthcare professionals, including 50 percent of U.S. physicians, who routinely use its intuitive solutions to help streamline workflow and improve patient care. The company also facilitates the delivery of valuable content and tools between partnering organizations and its members. For more information, please visit . Epocrates is a trademark of Epocrates, Inc., registered in the U.S. and other countries.

The Epocrates, Inc. logo is available at
CONTACT: Erica Sniad Morgenstern
         Senior Director, Public Relations and Communications
         Epocrates, Inc.
         (650) 227-6907

Epocrates, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs